Skip to content

Scholar Rock SRRK Current ratio

Current ratio at other companies

Biogen logo
BiogenBIIB
3.1×+1.6×
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
22.6×+1.6×
PTC Therapeutics logo
PTC TherapeuticsPTCT
2.4×-1.5×
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
19.9×-0.4×
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
7.1×+1.0×
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
15.1×+10.0×

Other financials

Income statement

See full
Revenue-
Operating income-$102.0M-32.3%
Net income-$105.5M-41.2%
EPS (diluted)-$0.83-23.9%

Balance sheet

See full
Cash & equivalents$430.5M+212%
Total debt$205.7M+226%
Total equity$276.0M-11.6%
Total assets$535.3M+31.3%

Cash flow

See full
Operating cash flow-$82.1M-4.4%
CapEx$68.0K-74.9%
Free cash flow-$82.2M-4.1%

Valuation

See full
Market cap$5.67B+85.5%

Profitability

See full
Operating margin-231.8%
Net margin-236.9%
FCF margin-309.1%

Returns & leverage

See full
Return on equity-138.9%+60.1pp
Debt / equity0.7×+0.5×

Where this comes from

Calculated from Scholar Rock’s reported figures.

Based on the most recent quarter.

The official record: Scholar Rock’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scholar Rock's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Scholar Rock's current ratio?
Scholar Rock (SRRK) reported current ratio of 8.6× in Q1 2026.
How has Scholar Rock's current ratio changed year-over-year?
Scholar Rock's current ratio decreased by 15.7% year-over-year, from 10.3× to 8.6×.
What is the long-term trend for Scholar Rock's current ratio?
Over 5 years (2020 to 2025), Scholar Rock's current ratio has grown at a -3.0% compound annual growth rate (CAGR), from 8.1× to 6.9×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.